Magenta Therapeutics, Inc. (MGTA): Price and Financial Metrics
GET POWR RATINGS... FREE!
MGTA Stock Price Chart Interactive Chart >
MGTA Price/Volume Stats
| Current price | $10.80 | 52-week high | $14.20 |
| Prev. close | $11.03 | 52-week low | $6.03 |
| Day low | $10.46 | Volume | 723,700 |
| Day high | $11.06 | Avg. volume | 260,307 |
| 50-day MA | $11.49 | Dividend yield | N/A |
| 200-day MA | $9.40 | Market Cap | 525.00M |
Magenta Therapeutics, Inc. (MGTA) Company Bio
Magenta Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Latest MGTA News From Around the Web
Below are the latest news stories about Magenta Therapeutics Inc that investors may wish to consider to help them evaluate MGTA as an investment opportunity.
Gene Therapy Companies Undervalued, Positioned for UpsidePharmaceutical companies can trade sideways for years, and may see a spike every now and then due to positive announcements or an FDA approval update. The newest subset of the biotech industry, known as gene therapy companies, has been multiplying at an astonishing rate. As a result, they have many new stocks listed to capital markets. These companies have recently piqued the interest of investors, and analysts are weighing in. Many individuals are born with disorders for which there is no cure, |
Magenta Therapeutics Appoints Thomas Beetham as Chief Legal OfficerCAMBRIDGE, Mass., Jun 14, 2021--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced the appointment of Thomas Beetham as Chief Legal Officer. |
B.Riley Financial Reaffirms Their Buy Rating on Magenta Therapeutics (MGTA)In a report released today, Kalpit Patel from B.Riley Financial reiterated a Buy rating on Magenta Therapeutics (MGTA), with a price target of The post B.Riley Financial Reaffirms Their Buy Rating on Magenta Therapeutics (MGTA) appeared first on Smarter Analyst . |
Mizuho Securities Reiterates Their Buy Rating on Magenta Therapeutics (MGTA)Mizuho Securities analyst Difei Yang reiterated a Buy rating on Magenta Therapeutics (MGTA) today and set a price target of $17.00. The post Mizuho Securities Reiterates Their Buy Rating on Magenta Therapeutics (MGTA) appeared first on Smarter Analyst . |
Magenta Therapeutics Announces Additional Preliminary Positive Results from Ongoing Phase 2 Clinical Trial of MGTA-145 and Plerixafor in Patients with Multiple Myeloma at the American Society of Clinical Oncology (ASCO) Annual MeetingMagenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced additional positive results from a Phase 2 clinical trial of MGTA-145 and plerixafor in patients with multiple myeloma at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually June 4-8, 2021. |
MGTA Price Returns
| 1-mo | -5.18% |
| 3-mo | -19.10% |
| 6-mo | 37.58% |
| 1-year | 11.46% |
| 3-year | -25.62% |
| 5-year | N/A |
| YTD | 37.76% |
| 2020 | -48.28% |
| 2019 | 165.96% |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...